Literature DB >> 11805310

Substance P, opioid, and catecholamine systems in the mouse central nervous system (CNS).

R G Hill1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11805310      PMCID： PMC117340          DOI： 10.1073/pnas.032663599

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  12 in total

1.  Proteinase-activated receptor-2 and hyperalgesia: A novel pain pathway.

Authors:  N Vergnolle; N W Bunnett; K A Sharkey; V Brussee; S J Compton; E F Grady; G Cirino; N Gerard; A I Basbaum; P Andrade-Gordon; M D Hollenberg; J L Wallace
Journal:  Nat Med       Date:  2001-07       Impact factor: 53.440

2.  The NK1 receptor mediates both the hyperalgesia and the resistance to morphine in mice lacking noradrenaline.

Authors:  Luc Jasmin; Duc Tien; David Weinshenker; Richard D Palmiter; Paul G Green; Gabriella Janni; Peter T Ohara
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

3.  Disruption of the dopamine beta-hydroxylase gene in mice suggests roles for norepinephrine in motor function, learning, and memory.

Authors:  S A Thomas; R D Palmiter
Journal:  Behav Neurosci       Date:  1997-06       Impact factor: 1.912

Review 4.  NK1 (substance P) receptor antagonists--why are they not analgesic in humans?

Authors:  R Hill
Journal:  Trends Pharmacol Sci       Date:  2000-07       Impact factor: 14.819

5.  Neurotransmitter candidates of somatosensory primary afferent fibres.

Authors:  T E Salt; R G Hill
Journal:  Neuroscience       Date:  1983-12       Impact factor: 3.590

6.  Effect of intrathecally administered noradrenergic antagonists on nociception in the rat.

Authors:  J Sagen; H K Proudfit
Journal:  Brain Res       Date:  1984-09-24       Impact factor: 3.252

Review 7.  Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists.

Authors:  N M Rupniak; M S Kramer
Journal:  Trends Pharmacol Sci       Date:  1999-12       Impact factor: 14.819

8.  Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.

Authors:  C C Chan; S Boyce; C Brideau; S Charleson; W Cromlish; D Ethier; J Evans; A W Ford-Hutchinson; M J Forrest; J Y Gauthier; R Gordon; M Gresser; J Guay; S Kargman; B Kennedy; Y Leblanc; S Leger; J Mancini; G P O'Neill; M Ouellet; D Patrick; M D Percival; H Perrier; P Prasit; I Rodger
Journal:  J Pharmacol Exp Ther       Date:  1999-08       Impact factor: 4.030

9.  Potentiated opioid analgesia in norepinephrine transporter knock-out mice.

Authors:  L M Bohn; F Xu; R R Gainetdinov; M G Caron
Journal:  J Neurosci       Date:  2000-12-15       Impact factor: 6.167

10.  5-hydroxytryptamine (5-HT)1A autoreceptor adaptive changes in substance P (neurokinin 1) receptor knock-out mice mimic antidepressant-induced desensitization.

Authors:  N Froger; A M Gardier; R Moratalla; I Alberti; I Lena; C Boni; C De Felipe; N M Rupniak; S P Hunt; C Jacquot; M Hamon; L Lanfumey
Journal:  J Neurosci       Date:  2001-10-15       Impact factor: 6.167
View more
  2 in total

Review 1.  Tachykinins and excitotoxicity in cerebellar granule cells.

Authors:  Cinzia Severini; Cristina Zona
Journal:  Cerebellum       Date:  2006       Impact factor: 3.847

2.  Effects of the NK1 antagonist, aprepitant, on response to oral and intranasal oxycodone in prescription opioid abusers.

Authors:  Sharon L Walsh; Markus Heilig; Paul A Nuzzo; Pam Henderson; Michelle R Lofwall
Journal:  Addict Biol       Date:  2012-01-19       Impact factor: 4.280
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.